Amarin Corp Plc (AMRN)

[ratna1]

Dear Jesse, once more my heartfelt thanks for your clear elucidation of facts for oh so many years!
Watching in amazement how raging bulls on this otherwise supreme board of assorted experts turned into meek sheep clamoring to offer themselves up to the stockyards to be butchered for a buy out in the 30$ range brings up the old latin primal question of any examination of legal mattes: CUI BONO?
"Who benefits" from this short attack?
Also one might ask as an investor how long can it be sustained?
MarketMakers need supply to throw at the market. Pretty soon we should see a supply run at least into the 23 - 24 $ range just out of mathematical necessities which should be as meaningless as the selloff.
All that matters is patients receiving prescriptions in unheard of numerical progression!

As to your topic #2 my search brought up this certainly anecdotal first person report of VASCEPA alleviating Erectile Dysfunction..... :

"dabe
Comments82 | + Follow
I started taking Vascepa around three weeks ago. I am 72, in good physical condition, have controlled hypertension and borderline high cholesterol. As is common with males my age, I have to use cialis to engage in sexual relations. My doctor only wrote the script for Vascepa after I gave him an education. He was vaguely familiar with the medication but was unaware of the specific CV benefits which surprised me given that he was doctor in a large volume multi-disciplinary practice owned and managed by a respected, renown teaching hospital. My desire to take Vascepa was primarily to conduct my own experiment on the anti-inflammatory potential of the drug and secondarily to treat my minor cardiovascular issues given my age. Another words I wanted to see if Vascepa would ameliorate ED. Well after three weeks of taking the drug I am noticing that I am waking up with a morning wood on a frequent basis which did not occur before I started taking the medication. Coincidence or something else? I obviously can’t answer that but so far I am very pleased with the results for my primary indication. The drug may have great potential as a treatment for diseases related to systemic inflammation as well as CV issues.
17 Dec 2019, 12:37 PM"
>https://seekingalpha.com/news/3526445-stifel-softens-view-on-amarin-after-fda-nod-on-vascepa-cv-claim<;

Now that would certainly bring in a few more headlines than something as common and trivial as MACE which nobody wants to think about anyway...
I wonder if the company's C-Suite is even slightly aware of this possible avenue?

Once again :
please keep up your enlightening contributions!